April 2015 – Page 2 – IPO Boutique

Secondaries announced 4.7.2015

Posted on April 7, 2015

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: New Residential Investment Corp. Symbol: NRZ Price: Last trade $15.37 Trade Date: 4/8 Shares: 40 million Underwriter(s) Citigroup Rating=Subscription Needed Company:[…]

Secondaries announced 4.6.2015

Posted on April 6, 2015

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Cerulean Pharma Inc. Symbol: CERU Price: Last trade $7.25 Trade Date: 4/7 Shares: 4.8 million Underwriter(s) Leerink Partner, Barclays Capital Co[…]

IPO Market Churning Up Deals for Next Week

Posted on April 6, 2015April 6, 2015

After an extremely light March consisting of only seven IPOs coming to market, it was a sigh of relief for new issues investors to see the number of filings come in Monday morning before the market opened. Since the market closed Thursday, a total of six deals set terms:

IPO Weekly Recap 4.3.2015 – GoDaddy IPO Speeds Out of the Gate

Posted on April 3, 2015April 3, 2015

This past week two IPOs debuted, one updated terms and ten new deals filed. In a holiday-shortened trading week, just two IPOs came to market and both had solid debuts. GoDaddy (NYSE: GDDY) ended up being reportedly 20x oversubscribed. The deal upsized and priced $1.00 above the range ($20.00) before opening 31% higher with a[…]

March 2015 IPO Track Record Recap

Posted on April 2, 2015April 2, 2015

It was another lighter month in terms of quantity of IPOs that came to market as just 7 deals priced. To draw a comparison to last year, in March 2014 a total of 25 IPOs priced. There have been a total of 30 deals that have priced thus far in 2015 as compared to 61[…]

Secondaries announced 4.1.2015

Posted on April 1, 2015

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Conatus Pharmaceuticals, Inc. Symbol: CNAT Price: Last trade $6.80 Trade Date: 4/2 Shares: 2.9 million Underwriter(s) Stifel, Roth Capital Partners Rating=Subscription[…]